Autopsy report · NCT00215657

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

“The doses were not effective in maintaining testosterone suppression”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 6 months after it had already started.
• Ran for about 3 years before it stopped.
• 131 participants enrolled.
• Results were posted on the registry 3 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Ferring Pharmaceuticals

Sponsor type

Industry

Conditions

Prostate Cancer

Interventions

Degarelix; Degarelix; Degarelix; Degarelix; Degarelix; Degarelix

Participants

131

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.